| Literature DB >> 34972144 |
Lu Lin1,2, Weiqin Liu1,2, Jing Mu1,2, Enmei Zhan1,2, Hong Wei1,2, Siqi Hong2,3, Ziyu Hua1,2.
Abstract
Prophylaxis of brain injury in newborns has been a main concern since the first neonatal neuronal intensive care unit (NNICU) was established in the world in 2008. The aim of this study was to outline and evaluate the unit's development by analyzing the demographics of the patients, the services delivered, the short-term outcomes before and after the establishment of NNICU. During the two investigation periods, 384 newborns were diagnosed or suspected as "neonatal encephalopathy", among which 185 patients admitted to NNICU between 2011.03.01 and 2012.09.30 before the establishment of NNICU were enrolled in the pre-NNICU group, another 199 neonates hospitalized during 2018.03.01 to 2019.09.30 were included in the post-NNICU group. Patients in the post-NNICU group were more likely to have seizures (P = 0.001), incomplete or absent primitive reflexes (P = 0.002), therapeutic hypothermia (P<0.001) and liquid control (P<0.001) in acute phase. Meanwhile, amplitude-integrated electro encephalogram (aEEG) monitoring (P<0.001) and cranial ultrasound (P<0.001) were more often used in NNICU. Both of the follow-up rate in brain MRI and the assessment of neurodevelopment at 3 months were higher in the post-NNICU group (P<0.001). In conclusion, the NNICU focused on the neonatal neurocritical care for the babies susceptible to NE with the guidance of evidence-based medicine, the establishment of NNICU is gradually improving and standardizing the neuroprotective therapy and clinical follow-up to improve neurodevelopmental prognosis of the NE patients in CHCMU.Entities:
Mesh:
Year: 2021 PMID: 34972144 PMCID: PMC8719725 DOI: 10.1371/journal.pone.0261837
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic features and risk factors of the neonates.
| Pre-NNICU (n = 185) | Post-NNICU (n = 199) |
|
| ||
|---|---|---|---|---|---|
| GA (week) | 38.64 (37.71–39.71) | 37.87 (36.14–38.00) | <0.001 | ||
| BW (g) | 3056.72(2700–3405) | 2946.26(2510–3000) | 0.050 | ||
| Gender | male | 60.50% (112) | 57.80% (115) | 0.300 | 0.584 |
| female | 39.50% (73) | 42.20% (83) | |||
| Abnormal delivery | 40.00% (74) | 53.30% (106) | 6.776 | 0.009 | |
| Single birth | 96.80% (179) | 87.90% (175) | 10.349 | 0.001 | |
| Mother’s age(years old) | 28.20(25.00–31.00) | 29.62(29.62±4.32) | 0.002 | ||
| GDM | 9.20% (17) | 26.80% (53) | 19.786 | <0.001 | |
| PIH | 7.6% (14) | 9.50% (19) | 0.479 | 0.489 | |
| ICP | 4.90% (9) | 8.50% (17) | 2.504 | 0.152 | |
| Intrauterine distress | 8.10% (15) | 11.60% (23) | 1.280 | 0.258 | |
| MSAF | 25.90% (48) | 15.60% (31) | 6.307 | 0.012 | |
| PROM | 20.00% (37) | 26.10% (52) | 2.204 | 0.155 | |
| dystocia | 3.80% (7) | 1.50% (3) | 1.958 | 0.162 | |
| Asphyxiation | 12.40% (23) | 12.60% (25) | 0.001 | 0.969 | |
| Hypoglycemia | 3.80% (7) | 19.10% (38) | 22.834 | <0.001 | |
| Sepsis | 1.10% (2) | 20.60% (41) | 37.900 | <0.001 | |
| Severe jaundice | 15.70% (29) | 11.10% (22) | 1.777 | 0.183 | |
| pH≤7.20 | 6.00% (7/116) | 2.60% (5/196) | 2.391 | 0.122 | |
*Abbreviation: GA gestational age; BW birth weight; GDM gestational diabetes mellitus; PIH pregnancy-induced hypertension; ICP intrahepatic cholestasis of pregnancy; MSAF meconium-stained amniotic fluid; PROM premature rupture of membranes.
Clinical features of the neonates.
| Pre-NNICU (n = 185) | Post-NNICU (n = 199) |
|
| ||
|---|---|---|---|---|---|
| Age of onset (days) | 4.94(0–7.5) | 5.11(0–8) | 0.397 | ||
| seizures | 9.20% (17) | 22.10% (44) | 11.980 | 0.001 | |
| Abnormal level of consciousness | 54.10% (100) | 61.80% (123) | 2.368 | 0.124 | |
| Hypotonia | 20.50% (38) | 18.60% (37) | 0.231 | 0.631 | |
| Incomplete primitive reflexes | 88.10% (163) | 96.50% (192) | 9.630 | 0.002 | |
| Hypothermia | 0 | 0.50% (1) | - | - | |
| Sarnat staging | <0.001 | ||||
| Less than Stage1 | 50.80% (94) | 31.20% (62) | 15.355 | <0.001 | |
| Stage1 | 5.90% (11) | 5.50% (11) | 0.031 | 0.860 | |
| Stage2 | 41.60% (77) | 58.80% (117) | 11.310 | 0.001 | |
| Stage3 | 1.60% (3) | 4.50% (9) | 2.665 | 0.103 | |
Neuromonitoring and neuroimaging of the neonates.
| Pre-NNICU (n = 185) | Post-NNICU (n = 199) |
|
| ||
|---|---|---|---|---|---|
| aEEG | 28 | 98 | 50.601 | <0.001 | |
| normal | 67.90% (19/28) | 80.60% (79/98) | 2.050 | 0.152 | |
| abnormal | mild | 32.10% (9/28) | 12.20% (12/98) | 6.208 | 0.013 |
| moderate | 0 | 7.10% (7/98) | 2.118 | 0.146 | |
| severe | 0 | 0 | - | - | |
| Ultrasound | 41 | 143 | 94.879 | <0.001 | |
| normal | 61.00% (25/41) | 62.90% (90/143) | 0.052 | 0.819 | |
| ventricular dilation | 29.30% (12/41) | 10.50% (15/143) | 8.974 | 0.003 | |
| cyst | 7.30% (3/41) | 21.00(30/143) | 4.041 | 0.044 | |
| IVH | I-II | 2.40% (1/41) | 3.50% (5/143) | 0.113 | 0.737 |
| III-IV | 0 | 2.10% (3/143) | 0.874 | 0.350 | |
| MRI (first time) | 69 | 93 | 3.500 | 0.061 | |
| Age at MRI (days) | 5.87 (0–8) | 25.52 (5.5–28.5) | <0.001 | ||
| Stage 0 | 29.00% (20/69) | 49.50% (46/93) | 6.880 | 0.009 | |
| Stage 1 | A | 36.20% (25/69) | 32.30% (30/93) | 0.279 | 0.597 |
| B | 21.70% (15/69) | 11.80% (11/93) | 2.888 | 0.089 | |
| Stage 2 | A | 5.80% (4/69) | 2.20% (2/93) | 1.477 | 0.224 |
| B | 7.20% (5/69) | 4.30% (4/93) | 0.655 | 0.418 | |
| Stage 3 | 0 | 0 | - | - | |
| MRI (second time) | 5.80% (4/69) | 28.00% (26/93) | 12.891 | <0.001 | |
| Age at 2nd time MRI (days) | 159.5 | 111.96(45.75–133) | 0.099 | ||
| Stage 0 | 4 | 61.50% (16/26) | |||
| Stage 1 | A | 0 | 34.60% (9/26) | ||
| B | 0 | 3.80% (1/26) | |||
| Stage 2 | A | 0 | 0 | ||
| B | 0 | 0 | |||
| Stage 3 | 0 | 0 | |||
| Improvement | 100% (4/4) | 92.30% (24/26) | 0.330 | 0.566 | |
| MRI (third time) | 0 | 3.22% (3/93) | |||
*Abbreviations: aEEG: amplitude-integrated electro encephalogram; IVH: intraventricular hemorrhage; MRI: magnetic resonance imaging.
Neuroprotective therapy of the neonates.
| Pre-NNICU (n = 185) | Post-NNICU (n = 199) |
|
| ||
|---|---|---|---|---|---|
| Hospitalization (days) | 12.00 (9–14) | 10.35 (6–14) | <0.001 | ||
| Therapeutic hypothermia (%) | 1.10 (2) | 8.00 (16) | 10.392 | 0.001 | |
| Fluid restriction (%) | 40.00 (74) | 62.80 (125) | 20.937 | <0.001 | |
| Neuroprotective medicine | 95.10 (176) | 16.60% (33) | 238.500 | <0.001 | |
| Prognosis (discharge) | improvement | 75.70% (140) | 84.40% (168) | 4.620 | 0.032 |
| deteriorate | 24.30% (45) | 15.60% (31) | |||
The assessment of neurodevelopment for the neonates.
| Pre-NNICU (N = 185) | Post-NNICU (N = 199) |
|
| ||
|---|---|---|---|---|---|
| 1st time (≤4 weeks) | 94.10% (174/185) | 66.80% (133/199) | 44.310 | <0.001 | |
| outcomes | normal | 66.70% (116/174) | 33.80% (45/133) | ||
| abnormal | 33.30% (58/174) | 66.20% (88/133) | 32.580 | <0.001 | |
| 2nd time (4–8 weeks) | 60.90% (106/174) | 75.20% (100/133) | 6.952 | 0.008 | |
| outcomes | improvement | 36.80% (39/106) | 36.00% (36/100) | ||
| deteriorate | 63.20% (67/106) | 64.00% (64/100) | 0.014 | 0.906 | |
| Follow-up at 3 months | 7.00% (13/185) | 25.60% (51/199) | 23.884 | <0.001 | |
| outcomes | normal | 61.50% (8/13) | 49.00% (25/51) | ||
| abnormal | 38.50% (5/13) | 51.00% (26/51) | 0.650 | 0.420 | |